Table 1.
Characteristics of the study population.
| cTnI <6 ng/L (n = 387) | cTnI 6–40 ng/L (n = 63) | cTnI > 40 ng/L (n = 35) | NT-proBNP >125 pg/ml (n = 159) | Total cohort (n = 485) | |
|---|---|---|---|---|---|
| Age (years) | 61 ± 15 | 62 ± 12 | 62 ± 18 | 63 ± 15 | 62 ± 15 |
| Women/men | 202/185 (52/48) | 22/41 (35/65) | 14/21 (40/60) | 68/91 (43/57) | 245/240 (51/49) |
| Systolic blood pressure (mmHg) | 122 ± 21 | 128 ± 20 | 130 ± 20 | 129 ± 21 | 130 ± 20 |
| Heart rate (bpm) | 78 ± 18 | 78 ± 17 | 85 ± 17 | 78 ± 17 | 79 ± 18 |
| Cardiotoxicity | 18 (5) | 8 (13) | 4 (11) | 21 (13) | 30 (6) |
| Comorbidities | |||||
| Coronary artery disease | 58 (15) | 15 (24) | 10 (29) | 40 (25) | 83 (17) |
| Smoking | 44 (11) | 14 (22) | 6 (17) | 33 (21) | 64 (13) |
| Atrial fibrillation | 38 (10) | 14 (22) | 7 (20) | 29 (18) | 59 (12) |
| Hypertension | 156 (40) | 33 (52) | 17 (49) | 60 (38) | 206 (42) |
| COPD | 21 (5) | 2 (3) | 1 (3) | 11 (7) | 24 (5) |
| Diabetes | 25 (6) | 13 (21) | 3 (9) | 23 (14) | 41 (8) |
| Hypercholesterolemia | 41 (11) | 12 (19) | 5 (14) | 30 (19) | 58 (129) |
| Stroke | 13 (3) | 4 (6) | 2 (6) | 9 (6) | 19 (4) |
| High-grade valvular disease | 5 (1) | 1 (2) | 3 (9) | 6 (4) | 9 (2) |
| Echocardiographic findings | |||||
| LVEF | |||||
| <40% | 24 (6) | 7 (11) | 11 (31) | 24 (15) | 42 (9) |
| 40–50% | 39 (10) | 20 (32) | 15 (43) | 62 (39) | 74 (15) |
| >50% | 334 (86) | 25 (40) | 10 (29) | 73 (46) | 369 (76) |
| Diastolic dysfunction | |||||
| I° | 46 (12) | 9 (14) | 4 (11) | 21 (13) | 59 (12) |
| II° | 22 (6) | 8 (13) | 3 (9) | 16 (10) | 33 (7) |
| III° | 2 (1) | 1 (2) | 3 (9) | 5 (3) | 6 (1) |
| Global longitudinal strain | |||||
| <−20 | 47 (12) | 20 (32) | 7 (20) | 43 (27) | 74 (15) |
| >−20 | 128 (33) | 8 (13) | 1 (3) | 16 (10) | 136 (28) |
| Symptoms | |||||
| Dyspnea (NYHA stage) | |||||
| NYHA I | 107 (28) | 7 (11) | 3 (9) | 27 (17) | 117 (24) |
| NYHA II | 151 (39) | 23 (37) | 13 (37) | 67 (42) | 187 (39) |
| NYHA III | 29 (7) | 10 (16) | 13 (37) | 39 (25) | 52 (11) |
| NYHA IV | 3 (1) | 0 (0) | 2 (6) | 4 (3) | 5 (1) |
| Angina pectoris (CCS stage) | |||||
| CCS I | 21 (5) | 7 (11) | 3 (9) | 17 (11) | 31 (6) |
| CCS II | 5 (1) | 1 (2) | 2 (6) | 4 (3) | 8 (2) |
| CCS III | 0 (0) | 0 (0) | 5 (14) | 5 (3) | 5 (1) |
Values are presented as the mean ± the standard deviation or the number of patients (percent).
bpm, beats per minute; cTnI, cardiac troponin I; CCS, Canadian Cardiovascular Society; COPD, chronic obstructive pulmonary disease; LVEF, left ventricular ejection fraction; n, number; NT-proBNP, N-terminal pro B-type natriuretic peptide; NYHA, New York Heart Association.